Revenue
2019
2020
2021
2022
2023
2024
2025
Allogene Therapeutics, Inc. (ALLO)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $22,000 | $95,000 | $156,000 | $114.1M | $0 | $0 | — |
| Research & development | $150.2M | $192.3M | $242.9M | $256.4M | $220.2M | $193.0M | $144.5M | $151.9M |
| Operating expenses | $209.3M | $273.2M | $327.8M | $335.7M | $294.3M | $258.2M | $202.0M | $192.8M |
| Operating income | −$209.3M | −$273.2M | −$327.7M | −$335.5M | −$180.2M | −$258.2M | −$202.0M | −$192.8M |
| EBITDAderived | −$197.0M | −$259.6M | −$313.5M | −$321.2M | −$169.7M | −$250.8M | −$197.4M | −$191.8M |
| Net income | −$190.9M | −$257.6M | −$327.3M | −$340.4M | −$182.1M | −$316.4M | −$184.6M | −$211.5M |
| Basic EPSper diluted share | -$0.87 | -$1.32 | -$2.09 | -$2.38 | -$1.34 | -$2.63 | -$1.83 | -$7.31 |
| Diluted EPSper diluted share | -$0.87 | -$1.32 | -$2.09 | -$2.38 | -$1.34 | -$2.63 | -$1.83 | -$7.31 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 21, 2026Form 4 | Yoshiyama AnnieSVP, Finance | SellCommon Stock | 9.6K | $2.31 | $22.1K | 124.5K |
| Mar 31, 2026Form 4 | Beneski Benjamin MachinasSVP, Chief Technical Officer | SellCommon Stock | 2.9K | $2.50 | $7.2K | 195.3K |
| Mar 16, 2026Form 4 | Beneski Benjamin MachinasSVP, Chief Technical Officer | SellCommon Stock | 4.8K | $2.47 | $11.9K | 198.2K |
| Mar 16, 2026Form 4 | Chang David DPresident and CEO | SellCommon Stock | 47.8K | $2.47 | $118.0K | 5.15M |
| Mar 2, 2026Form 4 | Beneski Benjamin MachinasSVP, Chief Technical Officer | SellCommon Stock | 7.1K | $2.60 | $18.5K | 203.0K |